The Chinese pharmaceutical company Hebei Changshan Biochemical Pharmaceutical (CSBIO) plans to build a plant in the Republic of Bashkortostan for the production of heparin. This medicine is used to thin the blood, as well as to treat cardiovascular diseases.
As specified, heparin is produced mainly from the mucous membrane of pig intestines, but in China there are not enough raw materials for its production. This was reported to Vedomosti by two participants at a meeting at the Ministry of Agriculture, where they discussed the possibility of such a project. The department confirmed the meeting and the agenda.
CSBIO is the leading heparin producer in China and its products are exported to 30 countries around the world. According to Bloomberg data for 2021, the company’s revenue was 2.9 billion yuan (35.2 billion rubles) and total assets amounted to 3.5 billion yuan (41, 6 billion rubles at the current exchange rate of April 14).
The new plant in the Republic of Bashkortostan is expected to increase the company’s production capacity and enable a greater supply of heparin, which could lead to better treatment of cardiovascular diseases.
Get the latest news today on The Eastern Herald.
